Patents by Inventor Jeremy Richman

Jeremy Richman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
    Publication number: 20070079392
    Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.
    Type: Application
    Filed: November 22, 2006
    Publication date: April 5, 2007
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Kevin Lowitz, David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly
  • Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
    Publication number: 20050154029
    Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.
    Type: Application
    Filed: August 31, 2004
    Publication date: July 14, 2005
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin Lowitz
  • Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
    Publication number: 20050004178
    Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.
    Type: Application
    Filed: July 23, 2004
    Publication date: January 6, 2005
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Kevin Lowitz
  • Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
    Publication number: 20040142377
    Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.
    Type: Application
    Filed: December 6, 2002
    Publication date: July 22, 2004
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: David J. Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Huong T. Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin P. Lowitz